Search
SOLACI Congress
HomeCONGRESS

CONGRESS

View Category
Coronary disease

EuroPCR 2019 | MeRes-1: Bioresorbable Scaffolds Return with Renewed Strength

A small number of highly selected patients presents good outcomes with new bioresorbable scaffold MeRes, but much...
solaci -
Learn More
STRUCTURAL HEART DISEASE

EuroPCR 2019 | Most Recent TAVR Meta-Analysis: The Spectrum of Treatment Reaches All Patients

This new meta-analysis combines all randomized transcatheter aortic valve replacement (TAVR) vs. surgical aortic valve replacement trials...
solaci -
Learn More
Femoropopliteal

EuroPCR 2019 | EFFPAC: New Peripheral Paclitaxel Coated Balloons, Efficacy with no Sign of Mortality

Paclitaxel coated balloons in peripheral territory have been under the spotlight for alleged increased mortality, which even...
solaci -
Learn More
STRUCTURAL HEART DISEASE

EuroPCR 2019 | Leaflex: New Device for Pre-TAVR Calcium Fracture

Researchers behind this small study believe that fracturing the rigid calcium deposits on leaflets with this new...
solaci -
Learn More
PERIPHERAL VASCULAR DISEASE

EuroPCR 2019 | TAVR Durability Offers Certain Guarantees at 8 and 10 Years

It has been 3 years since EuroPCR 2016 and the presentation of the first data on possible...
solaci -
Learn More
STRUCTURAL HEART DISEASE

EuroPCR 2019 | Long-Term Follow-Up for New Left Bundle Branch Block After TAVR Is Reassuring with Certain Precautions

Long-term follow-up of patients who underwent transcatheter aortic valve replacement (TAVR) and developed left bundle branch block...
solaci -
Learn More
Coronary disease

EuroPCR 2019 | Stent Firehawk Continues to Show Good Results at 2 Years vs. Xience

This device, an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent manufactured in China, showed very similar efficacy and safety...
solaci -
Learn More
Acute coronary syndromes

EuroPCR 2019 | BASKET-SMALL 2: Drug-Coated Balloons vs. DES in Small Vessels

This angiographic substudy supports the safety of drug-coated balloons in small vessels. Despite better angiographic outcomes, there...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Dr. Juan Manuel Pérez - 0
Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy